English

Neos Therapeutics, Inc.

EDGAR

NEOS Quarterly report (10-Q) · filed 2020-11-09

28 filing records in this dataset, filed from 2015-06-19 to 2020-11-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

12.5 million Unit_Standard_USD_L2WGQO9_3U2JYNCmyARAEQ

2020 Q3 · Unit_Standard_USD_L2WGQO9_3U2JYNCmyARAEQ

Exact inputs and evidence

Revenue: 12535000 Unit_Standard_USD_L2WGQO9_3U2JYNCmyARAEQ Source

Operating margin

-23.26%

2020 Q3 · %

Exact inputs and evidence

Operating Income: -2916000 Unit_Standard_USD_L2WGQO9_3U2JYNCmyARAEQ Source
Revenue: 12535000 Unit_Standard_USD_L2WGQO9_3U2JYNCmyARAEQ Source

Cash and cash equivalents: 12.7 million Unit_Standard_USD_L2WGQO9_3U2JYNCmyARAEQ 2020-09-30 Source
Exact value

12744000 Unit_Standard_USD_L2WGQO9_3U2JYNCmyARAEQ
Long-term debt including current maturities: Not available
Shares outstanding: 49.8 million Unit_Standard_shares_LQ17Drnbn0-XhJ-3XrybYg 2020-09-30 Source
Exact value

49755094 Unit_Standard_shares_LQ17Drnbn0-XhJ-3XrybYg

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

-5.68 million Unit12

2019-04-01 – 2020-03-31

Exact inputs and evidence

Operating cash flow: -7860000 Unit12 · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -6103000 Unit12 · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -12019000 Unit12 · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -7860000 Unit12 · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -10783000 Unit12 · 2019-01-01 – 2019-12-31 Source
Operating cash flow: -12019000 Unit12 · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -999000 Unit12 · 2020-01-01 – 2020-03-31 Source

Capital expenditure

1.08 million Unit12

2019-04-01 – 2020-03-31

Exact inputs and evidence

Capital expenditure: 365000 Unit12 · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 167000 Unit12 · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 748000 Unit12 · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 365000 Unit12 · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 1088000 Unit12 · 2019-01-01 – 2019-12-31 Source
Capital expenditure: 748000 Unit12 · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 160000 Unit12 · 2020-01-01 – 2020-03-31 Source

Free cash flow

-6.76 million Unit12

2019-04-01 – 2020-03-31

Exact inputs and evidence

Operating cash flow: -7860000 Unit12 · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -6103000 Unit12 · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -12019000 Unit12 · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -7860000 Unit12 · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -10783000 Unit12 · 2019-01-01 – 2019-12-31 Source
Operating cash flow: -12019000 Unit12 · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -999000 Unit12 · 2020-01-01 – 2020-03-31 Source
Capital expenditure: 365000 Unit12 · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 167000 Unit12 · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 748000 Unit12 · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 365000 Unit12 · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 1088000 Unit12 · 2019-01-01 – 2019-12-31 Source
Capital expenditure: 748000 Unit12 · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 160000 Unit12 · 2020-01-01 – 2020-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-11-09.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2019-12-31
Operating income: 7 of 11 periods available· newest 2019-12-31
Net income: Multiple units; comparison withheld· newest 2019-12-31
Operating cash flow: 7 of 11 periods available· newest 2019-12-31
Capital expenditure: 7 of 11 periods available· newest 2019-12-31
Total assets: Multiple units; comparison withheld· newest 2019-12-31
liabilities: No compatible figures in this window
Current assets: Multiple units; comparison withheld· newest 2019-12-31
Current liabilities: Multiple units; comparison withheld· newest 2019-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2019-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+29.3%

Prior period

Unit12 49.99 million

2018-01-01 – 2018-12-31
Current period

Unit12 64.65 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

64649000 − 49988000 = 14661000 Unit12

49988000 Unit12 · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
64649000 Unit12 · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Neos Therapeutics, Inc. · 2019-12-31 Neos Therapeutics, Inc. (edgar:1467652) Year-over-year change in Revenue: 14661000 Unit12 Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 64649000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#2124990 Filing: 000155837020002684 Input fundies:Revenue: 49988000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#2122688 Filing: 000155837020002684
The citation records this snapshot. The page link may show a newer release later.
Net income
+Unit12 34.77 million

Prior period

−Unit12 51.68 million

2018-01-01 – 2018-12-31
Current period

−Unit12 16.9 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-16902000 − -51675000 = 34773000 Unit12

-51675000 Unit12 · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-16902000 Unit12 · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Neos Therapeutics, Inc. · 2019-12-31 Neos Therapeutics, Inc. (edgar:1467652) Year-over-year change in Net income: 34773000 Unit12 Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -16902000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1931346 Filing: 000155837020002684 Input fundies:NetIncome: -51675000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1930872 Filing: 000155837020002684
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit12 30.66 million

Prior period

−Unit12 41.44 million

2018-01-01 – 2018-12-31
Current period

−Unit12 10.78 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-10783000 − -41441000 = 30658000 Unit12

-41441000 Unit12 · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-10783000 Unit12 · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Neos Therapeutics, Inc. · 2019-12-31 Neos Therapeutics, Inc. (edgar:1467652) Year-over-year change in Operating cash flow: 30658000 Unit12 Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -10783000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1930070 Filing: 000155837020002684 Input fundies:OperatingCashFlow: -41441000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1929877 Filing: 000155837020002684
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-20.1%

Prior period

Unit12 1.36 million

2018-01-01 – 2018-12-31
Current period

Unit12 1.09 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

1088000 − 1361000 = -273000 Unit12

1361000 Unit12 · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
1088000 Unit12 · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Neos Therapeutics, Inc. · 2019-12-31 Neos Therapeutics, Inc. (edgar:1467652) Year-over-year change in Capital expenditure: -273000 Unit12 Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1088000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1961218 Filing: 000155837020002684 Input fundies:CapitalExpenditure: 1361000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1961027 Filing: 000155837020002684
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue Unit12 64.65 million 100% of revenue
Operating costs Derived Unit12 75.06 million 116% of revenue
Operating income −Unit12 10.42 million −16% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −Unit12 10.78 million −17% of revenue
Capital expenditure Unit12 1.09 million 1.7% of revenue
Free cash flow Derived −Unit12 11.87 million −18% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	1044000	18132000 Derived	-17088000	Unavailable	Unavailable	-16974000 Derived	Source 2013-01-01 – 2013-12-31: 1044000 Unit12 Inspect Revenue Open source 2013-01-01 – 2013-12-31: -17088000 Unit12 Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -14955000 Unit12 Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 2019000 Unit12 Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	758000	19230000 Derived	-18472000	Unavailable	Unavailable	-17729000 Derived	Source 2014-01-01 – 2014-12-31: 758000 Unit12 Inspect Revenue Open source 2014-01-01 – 2014-12-31: -18472000 Unit12 Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -17390000 Unit12 Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 339000 Unit12 Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	3792000	30370000 Derived	-26578000	Unavailable	Unavailable	-26890000 Derived	Source 2015-01-01 – 2015-12-31: 3792000 Unit12 Inspect Revenue Open source 2015-01-01 – 2015-12-31: -26578000 Unit12 Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -25867000 Unit12 Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 1023000 Unit12 Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	10033000	85857000 Derived	-75824000	Unavailable	Unavailable	-74196000 Derived	Source 2016-01-01 – 2016-12-31: 10033000 Unit12 Inspect Revenue Open source 2016-01-01 – 2016-12-31: -75824000 Unit12 Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -70646000 Unit12 Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 3550000 Unit12 Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	27132000	83673000 Derived	-56541000	Unavailable	Unavailable	-55758000 Derived	Source 2017-01-01 – 2017-12-31: 27132000 Unit12 Inspect Revenue Open source 2017-01-01 – 2017-12-31: -56541000 Unit12 Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -53261000 Unit12 Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2497000 Unit12 Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	49988000	93484000 Derived	-43496000	Unavailable	Unavailable	-42802000 Derived	Source 2018-01-01 – 2018-12-31: 49988000 Unit12 Inspect Revenue Open source 2018-01-01 – 2018-12-31: -43496000 Unit12 Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -41441000 Unit12 Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1361000 Unit12 Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	64649000	75064000 Derived	-10415000	Unavailable	Unavailable	-11871000 Derived	Source 2019-01-01 – 2019-12-31: 64649000 Unit12 Inspect Revenue Open source 2019-01-01 – 2019-12-31: -10415000 Unit12 Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -10783000 Unit12 Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1088000 Unit12 Inspect Capital Expenditure Open source

Amounts are exact, in Unit12.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit12 64.6M 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-12-31	Revenue	1044000	Revenue: 1044000 Open source
20142014-12-31	Revenue	758000	Revenue: 758000 Open source
20152015-12-31	Revenue	3792000	Revenue: 3792000 Open source
20162016-12-31	Revenue	10033000	Revenue: 10033000 Open source
20172017-12-31	Revenue	27132000	Revenue: 27132000 Open source
20182018-12-31	Revenue	49988000	Revenue: 49988000 Open source
20192019-12-31	Revenue	64649000	Revenue: 64649000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

29.3% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 1044000 Open source
20142014-12-31	Year over year	-27.4%	Revenue: 758000 Open source Revenue: 1044000 Open source
20152015-12-31	Year over year	400.3%	Revenue: 3792000 Open source Revenue: 758000 Open source
20162016-12-31	Year over year	164.6%	Revenue: 10033000 Open source Revenue: 3792000 Open source
20172017-12-31	Year over year	170.4%	Revenue: 27132000 Open source Revenue: 10033000 Open source
20182018-12-31	Year over year	84.2%	Revenue: 49988000 Open source Revenue: 27132000 Open source
20192019-12-31	Year over year	29.3%	Revenue: 64649000 Open source Revenue: 49988000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -16.1% 2019

Free cash flow margin -18.4% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-1,636.8%	Operating Income: -17088000 Open source Revenue: 1044000 Open source
20142014-12-31	Operating margin	-2,436.9%	Operating Income: -18472000 Open source Revenue: 758000 Open source
20152015-12-31	Operating margin	-700.9%	Operating Income: -26578000 Open source Revenue: 3792000 Open source
20162016-12-31	Operating margin	-755.7%	Operating Income: -75824000 Open source Revenue: 10033000 Open source
20172017-12-31	Operating margin	-208.4%	Operating Income: -56541000 Open source Revenue: 27132000 Open source
20182018-12-31	Operating margin	-87%	Operating Income: -43496000 Open source Revenue: 49988000 Open source
20192019-12-31	Operating margin	-16.1%	Operating Income: -10415000 Open source Revenue: 64649000 Open source
2013-12-31	Net margin	Not reported	Revenue: 1044000 Open source
2014-12-31	Net margin	Not reported	Revenue: 758000 Open source
2015-12-31	Net margin	Not reported	Revenue: 3792000 Open source
2016-12-31	Net margin	Not reported	Revenue: 10033000 Open source
2017-12-31	Net margin	Not reported	Revenue: 27132000 Open source
2018-12-31	Net margin	Not reported	Revenue: 49988000 Open source
2019-12-31	Net margin	Not reported	Revenue: 64649000 Open source
20132013-12-31	Free cash flow margin	-1,625.9%	Revenue: 1044000 Open source Operating Cash Flow: -14955000 Open source Capital Expenditure: 2019000 Open source
20142014-12-31	Free cash flow margin	-2,338.9%	Revenue: 758000 Open source Operating Cash Flow: -17390000 Open source Capital Expenditure: 339000 Open source
20152015-12-31	Free cash flow margin	-709.1%	Revenue: 3792000 Open source Operating Cash Flow: -25867000 Open source Capital Expenditure: 1023000 Open source
20162016-12-31	Free cash flow margin	-739.5%	Revenue: 10033000 Open source Operating Cash Flow: -70646000 Open source Capital Expenditure: 3550000 Open source
20172017-12-31	Free cash flow margin	-205.5%	Revenue: 27132000 Open source Operating Cash Flow: -53261000 Open source Capital Expenditure: 2497000 Open source
20182018-12-31	Free cash flow margin	-85.6%	Revenue: 49988000 Open source Operating Cash Flow: -41441000 Open source Capital Expenditure: 1361000 Open source
20192019-12-31	Free cash flow margin	-18.4%	Revenue: 64649000 Open source Operating Cash Flow: -10783000 Open source Capital Expenditure: 1088000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit12 -10.8M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-12-31	Operating cash flow	-14955000	Operating Cash Flow: -14955000 Open source
20142014-12-31	Operating cash flow	-17390000	Operating Cash Flow: -17390000 Open source
20152015-12-31	Operating cash flow	-25867000	Operating Cash Flow: -25867000 Open source
20162016-12-31	Operating cash flow	-70646000	Operating Cash Flow: -70646000 Open source
20172017-12-31	Operating cash flow	-53261000	Operating Cash Flow: -53261000 Open source
20182018-12-31	Operating cash flow	-41441000	Operating Cash Flow: -41441000 Open source
20192019-12-31	Operating cash flow	-10783000	Operating Cash Flow: -10783000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit12 -11.9M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-12-31	Free cash flow	-16974000	Operating Cash Flow: -14955000 Open source Capital Expenditure: 2019000 Open source
20142014-12-31	Free cash flow	-17729000	Operating Cash Flow: -17390000 Open source Capital Expenditure: 339000 Open source
20152015-12-31	Free cash flow	-26890000	Operating Cash Flow: -25867000 Open source Capital Expenditure: 1023000 Open source
20162016-12-31	Free cash flow	-74196000	Operating Cash Flow: -70646000 Open source Capital Expenditure: 3550000 Open source
20172017-12-31	Free cash flow	-55758000	Operating Cash Flow: -53261000 Open source Capital Expenditure: 2497000 Open source
20182018-12-31	Free cash flow	-42802000	Operating Cash Flow: -41441000 Open source Capital Expenditure: 1361000 Open source
20192019-12-31	Free cash flow	-11871000	Operating Cash Flow: -10783000 Open source Capital Expenditure: 1088000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Liabilities / assets	Not reported	No source recorded
2014-12-31	Liabilities / assets	Not reported	No source recorded
2015-12-31	Liabilities / assets	Not reported	No source recorded
2016-12-31	Liabilities / assets	Not reported	No source recorded
2017-12-31	Liabilities / assets	Not reported	No source recorded
2018-12-31	Liabilities / assets	Not reported	No source recorded
2019-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Current assets / current liabilities	Not reported	No source recorded
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
2015-12-31	Current assets / current liabilities	Not reported	No source recorded
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
2017-12-31	Current assets / current liabilities	Not reported	No source recorded
2018-12-31	Current assets / current liabilities	Not reported	No source recorded
2019-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	Unavailable Not reported for this period.	−Unit12 14.96 million Exact value Exact value: -14955000 Unit12 2013-01-01 – 2013-12-31: -14955000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neos Therapeutics, Inc. · 2013-12-31 Neos Therapeutics, Inc. (edgar:1467652) Operating Cash Flow: -14955000 Unit12 Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -14955000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746916011314/neos-20151231.xml#1714970 Filing: 000104746916011314 The citation records this snapshot. The page link may show a newer release later.	Unit12 2.02 million Exact value Exact value: 2019000 Unit12 2013-01-01 – 2013-12-31: 2019000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neos Therapeutics, Inc. · 2013-12-31 Neos Therapeutics, Inc. (edgar:1467652) Capital Expenditure: 2019000 Unit12 Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 2019000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746916011314/neos-20151231.xml#1763124 Filing: 000104746916011314 The citation records this snapshot. The page link may show a newer release later.	−Unit12 16.97 million Calculation and evidence -14955000 − 2019000 Unit12 Exact free cash flow: -16974000 Unit12 2013-01-01 – 2013-12-31: -14955000 Unit12 · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 2019000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neos Therapeutics, Inc. · 2013-12-31 Neos Therapeutics, Inc. (edgar:1467652) Free cash flow: -16974000 Unit12 Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14955000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746916011314/neos-20151231.xml#1714970 Filing: 000104746916011314 Input fundies:CapitalExpenditure: 2019000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746916011314/neos-20151231.xml#1763124 Filing: 000104746916011314 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	Unavailable Not reported for this period.	−Unit12 17.39 million Exact value Exact value: -17390000 Unit12 2014-01-01 – 2014-12-31: -17390000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neos Therapeutics, Inc. · 2014-12-31 Neos Therapeutics, Inc. (edgar:1467652) Operating Cash Flow: -17390000 Unit12 Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -17390000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746917001586/neos-20161231.xml#1742816 Filing: 000104746917001586 The citation records this snapshot. The page link may show a newer release later.	Unit12 339,000 Exact value Exact value: 339000 Unit12 2014-01-01 – 2014-12-31: 339000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neos Therapeutics, Inc. · 2014-12-31 Neos Therapeutics, Inc. (edgar:1467652) Capital Expenditure: 339000 Unit12 Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 339000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746917001586/neos-20161231.xml#1790558 Filing: 000104746917001586 The citation records this snapshot. The page link may show a newer release later.	−Unit12 17.73 million Calculation and evidence -17390000 − 339000 Unit12 Exact free cash flow: -17729000 Unit12 2014-01-01 – 2014-12-31: -17390000 Unit12 · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 339000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neos Therapeutics, Inc. · 2014-12-31 Neos Therapeutics, Inc. (edgar:1467652) Free cash flow: -17729000 Unit12 Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17390000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746917001586/neos-20161231.xml#1742816 Filing: 000104746917001586 Input fundies:CapitalExpenditure: 339000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746917001586/neos-20161231.xml#1790558 Filing: 000104746917001586 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	Unavailable Not reported for this period.	−Unit12 25.87 million Exact value Exact value: -25867000 Unit12 2015-01-01 – 2015-12-31: -25867000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neos Therapeutics, Inc. · 2015-12-31 Neos Therapeutics, Inc. (edgar:1467652) Operating Cash Flow: -25867000 Unit12 Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -25867000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746918001730/neos-20171231.xml#1667349 Filing: 000104746918001730 The citation records this snapshot. The page link may show a newer release later.	Unit12 1.02 million Exact value Exact value: 1023000 Unit12 2015-01-01 – 2015-12-31: 1023000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neos Therapeutics, Inc. · 2015-12-31 Neos Therapeutics, Inc. (edgar:1467652) Capital Expenditure: 1023000 Unit12 Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 1023000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746918001730/neos-20171231.xml#1796390 Filing: 000104746918001730 The citation records this snapshot. The page link may show a newer release later.	−Unit12 26.89 million Calculation and evidence -25867000 − 1023000 Unit12 Exact free cash flow: -26890000 Unit12 2015-01-01 – 2015-12-31: -25867000 Unit12 · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1023000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neos Therapeutics, Inc. · 2015-12-31 Neos Therapeutics, Inc. (edgar:1467652) Free cash flow: -26890000 Unit12 Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25867000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746918001730/neos-20171231.xml#1667349 Filing: 000104746918001730 Input fundies:CapitalExpenditure: 1023000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746918001730/neos-20171231.xml#1796390 Filing: 000104746918001730 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	−Unit12 70.65 million Exact value Exact value: -70646000 Unit12 2016-01-01 – 2016-12-31: -70646000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neos Therapeutics, Inc. · 2016-12-31 Neos Therapeutics, Inc. (edgar:1467652) Operating Cash Flow: -70646000 Unit12 Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -70646000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746919001344/neos-20181231.xml#1703917 Filing: 000104746919001344 The citation records this snapshot. The page link may show a newer release later.	Unit12 3.55 million Exact value Exact value: 3550000 Unit12 2016-01-01 – 2016-12-31: 3550000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neos Therapeutics, Inc. · 2016-12-31 Neos Therapeutics, Inc. (edgar:1467652) Capital Expenditure: 3550000 Unit12 Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 3550000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746919001344/neos-20181231.xml#1879691 Filing: 000104746919001344 The citation records this snapshot. The page link may show a newer release later.	−Unit12 74.2 million Calculation and evidence -70646000 − 3550000 Unit12 Exact free cash flow: -74196000 Unit12 2016-01-01 – 2016-12-31: -70646000 Unit12 · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 3550000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neos Therapeutics, Inc. · 2016-12-31 Neos Therapeutics, Inc. (edgar:1467652) Free cash flow: -74196000 Unit12 Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70646000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746919001344/neos-20181231.xml#1703917 Filing: 000104746919001344 Input fundies:CapitalExpenditure: 3550000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000104746919001344/neos-20181231.xml#1879691 Filing: 000104746919001344 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−Unit12 53.26 million Exact value Exact value: -53261000 Unit12 2017-01-01 – 2017-12-31: -53261000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neos Therapeutics, Inc. · 2017-12-31 Neos Therapeutics, Inc. (edgar:1467652) Operating Cash Flow: -53261000 Unit12 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -53261000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1929684 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.	Unit12 2.5 million Exact value Exact value: 2497000 Unit12 2017-01-01 – 2017-12-31: 2497000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neos Therapeutics, Inc. · 2017-12-31 Neos Therapeutics, Inc. (edgar:1467652) Capital Expenditure: 2497000 Unit12 Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 2497000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1960836 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.	−Unit12 55.76 million Calculation and evidence -53261000 − 2497000 Unit12 Exact free cash flow: -55758000 Unit12 2017-01-01 – 2017-12-31: -53261000 Unit12 · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2497000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neos Therapeutics, Inc. · 2017-12-31 Neos Therapeutics, Inc. (edgar:1467652) Free cash flow: -55758000 Unit12 Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -53261000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1929684 Filing: 000155837020002684 Input fundies:CapitalExpenditure: 2497000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1960836 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	Unavailable Not reported for this period.	−Unit12 41.44 million Exact value Exact value: -41441000 Unit12 2018-01-01 – 2018-12-31: -41441000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neos Therapeutics, Inc. · 2018-12-31 Neos Therapeutics, Inc. (edgar:1467652) Operating Cash Flow: -41441000 Unit12 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -41441000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1929877 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.	Unit12 1.36 million Exact value Exact value: 1361000 Unit12 2018-01-01 – 2018-12-31: 1361000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neos Therapeutics, Inc. · 2018-12-31 Neos Therapeutics, Inc. (edgar:1467652) Capital Expenditure: 1361000 Unit12 Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 1361000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1961027 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.	−Unit12 42.8 million Calculation and evidence -41441000 − 1361000 Unit12 Exact free cash flow: -42802000 Unit12 2018-01-01 – 2018-12-31: -41441000 Unit12 · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1361000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neos Therapeutics, Inc. · 2018-12-31 Neos Therapeutics, Inc. (edgar:1467652) Free cash flow: -42802000 Unit12 Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41441000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1929877 Filing: 000155837020002684 Input fundies:CapitalExpenditure: 1361000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1961027 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	Unavailable Not reported for this period.	−Unit12 10.78 million Exact value Exact value: -10783000 Unit12 2019-01-01 – 2019-12-31: -10783000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Neos Therapeutics, Inc. · 2019-12-31 Neos Therapeutics, Inc. (edgar:1467652) Operating Cash Flow: -10783000 Unit12 Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -10783000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1930070 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.	Unit12 1.09 million Exact value Exact value: 1088000 Unit12 2019-01-01 – 2019-12-31: 1088000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Neos Therapeutics, Inc. · 2019-12-31 Neos Therapeutics, Inc. (edgar:1467652) Capital Expenditure: 1088000 Unit12 Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 1088000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1961218 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.	−Unit12 11.87 million Calculation and evidence -10783000 − 1088000 Unit12 Exact free cash flow: -11871000 Unit12 2019-01-01 – 2019-12-31: -10783000 Unit12 · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1088000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Neos Therapeutics, Inc. · 2019-12-31 Neos Therapeutics, Inc. (edgar:1467652) Free cash flow: -11871000 Unit12 Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:16Z Snapshot: b96b4b20aab70c5110d3250e67eebbfbdadba7fa8b3c3e2530e386b070865aff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1467652?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10783000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1930070 Filing: 000155837020002684 Input fundies:CapitalExpenditure: 1088000 Unit12 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/neos-20191231.xml#1961218 Filing: 000155837020002684 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

28 filings · 1,806 latest values · 1,806 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001467652, 1467652, NEOS, edgar:1467652, neos

Also known as Neos Therapeutics, Inc.

Neos Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Trailing twelve months

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation